The protein has a molecular weight of about 60280.90 Da (Table ) with a theoretical pI of 6.08 (6.30*). The protein has the total number of positively charged residues (Arg + Lys), the whole number of atoms, and the absolute number of negatively charged residues (Asp + Glu) as of 46, 8584, and 48, respectively. As more protein therapies are being developed, many of which have a short plasma half-life, the biotech and pharmaceutical industries are focusing more and more on methods to lengthen that half-life . The therapeutic and cost benefits of a longer half-life are apparent. Numerous recognized or in-development biotherapeutics have a short half-life, needing numerous administrations to sustain a therapeutic level over a long period . The use of half-life extension techniques permits the production of medicines with enhanced pharmacokinetic and pharmacodynamic characteristics that have a prolonged half-life. Incorporating half-life extension methods into developing numerous biotherapeutics is now standard practice. Various options are available for fine-tuning half-life and adaptation to the desired treatment method and condition . The anticipated protein half-life as of 30 hours (mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo); and >10 hours (Escherichia coli, in vivo).